Latest News and Press Releases

– Total 2021 Net Revenue of $42.3 Million – – FOTIVDA® (tivozanib) U.S. Net Product Revenue of $38.9 Million since March 22, 2021 – – FOTIVDA U.S. Net Product Revenue of $16.8 Million for 4Q 2021,...

BOSTON, March 07, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that it will report full year 2021 financial...

Five year follow-up data show FOTIVDA® (tivozanib) patients up to 5X more likely to experience long-term PFS compared to Nexavar® (sorafenib) Long-term data from pivotal TIVO-3 study continue to...

BOSTON, Feb. 03, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that members of its senior management team...

First line cohort of the Phase 1b/2 DEDUCTIVE study demonstrates promising efficacy and tolerability of tivozanib plus durvalumab in first line HCC Two trials in progress posters presentations for...

BOSTON, Jan. 04, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today highlighted its recent progress and outlook for 2022. ...

BOSTON, Jan. 04, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that it has entered into a clinical trial...

BOSTON, Dec. 22, 2021 (GLOBE NEWSWIRE) -- AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that members of its senior management team...